<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736735</url>
  </required_header>
  <id_info>
    <org_study_id>CTST-24</org_study_id>
    <nct_id>NCT01736735</nct_id>
  </id_info>
  <brief_title>Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects</brief_title>
  <acronym>STEPWISE</acronym>
  <official_title>A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorbent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorbent Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled study to determine the effect of CLP in heart failure subjects
      with fluid overload.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite endpoint comprised of: 6-Minute Walk Test, Body weight, KCCQ Score, Log2 NT-proBNP, time to first occurrence of heart/renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart/renal failure or death</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite endpoint for the change from baseline to 8 weeks comprised of the following:  6-Minute Walk Test (6 MWT), Body weight, KCCQ Score, Log2 NT-proBNP, time to first occurrence of heart failure or renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart failure or renal failure, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-Minute Walk Test distance from baseline to Week 8.</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to heart failure or renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart failure or renal failure, or death</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CLP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLP BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BID powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLP</intervention_name>
    <arm_group_label>CLP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:

          -  Age 21 years or older at randomization

          -  Heart failure with at least one of the following signs of current fluid overload:

               1. Peripheral (or sacral) edema &gt;1+ or ascites during screening or on day of
                  randomization

               2. Pulmonary congestion as determined by chest X-ray during the screening period

          -  Ambulatory and able to perform the 6-minute walk test

        Selected Exclusion Criteria:

          -  Participation in another clinical trial of an investigational or marketed drug within
             30 days or 5 half-lives (whichever is longer) preceding screening

          -  Any hospitalization or unscheduled outpatient decongestion therapy using IV
             diuretics, ultrafiltration, or paracentesis within 8 weeks prior to or during
             screening

          -  Coronary-artery bypass graft, percutaneous intervention (e.g., cardiac,
             cerebrovascular, aortic), or major surgery including thoracic and cardiac, within 2
             months prior to or during screening or anticipated need during study participation

          -  Heart transplant recipient, or anticipated need for transplant or LVAD during study
             participation

          -  Any of the following events having occurred within 8 weeks prior to or during
             screening: myocardial infarction, transient ischemic attack, stroke, or acute
             coronary syndrome as judged by the Investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Dittrich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sorbent Therapeutics, Study Sponsor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jade Brennan</last_name>
    <phone>919-491-5721</phone>
    <email>jadebrennan@momentum-research.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Chang</last_name>
    <email>jchang@sorbent.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orange Country Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joel Neutel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
